Fig. 4: Kaplan-Meier survival curves for patients undergoing hepatectomy versus those who refused to undergo hepatectomy after neoadjuvant triple therapy (excluding 16 patients who lost the opportunity due to tumor progression). | Communications Medicine

Fig. 4: Kaplan-Meier survival curves for patients undergoing hepatectomy versus those who refused to undergo hepatectomy after neoadjuvant triple therapy (excluding 16 patients who lost the opportunity due to tumor progression).

From: Neoadjuvant transarterial chemoembolization with tyrosine kinase and immune checkpoint inhibitors improves survival from resectable hepatocellular carcinoma in a multicenter, retrospective study (GUIDANCE002)

Fig. 4: Kaplan-Meier survival curves for patients undergoing hepatectomy versus those who refused to undergo hepatectomy after neoadjuvant triple therapy (excluding 16 patients who lost the opportunity due to tumor progression).The alternative text for this image may have been generated using AI.

a overall survival; b event-free survival. CI confidence interval; neoadjuvant triple therapy, neoadjuvant transarterial chemoembolization combined with immune checkpoint inhibitors and tyrosine kinase inhibitors.

Back to article page